Список литературы

Поставить закладку

Каприн А. Д., Рожкова Н. И. Маммология: национальное руководство //М.: Геотар-Медиа. – 2016., ГЭОТАР-Мед. Москва.
Early life factors and incidence of proliferative benign breast disease //Cancer Epidemiology and Prevention Biomarkers. – 2005. – Т. 14. – №. 12.
Berkey C. S. et al. Prospective study of growth and development in older girls and risk of benign breast disease in young women //Cancer. – 2011. – Т. 117. – №. 8. – С. 1612-1620.
Baer H. J. et al. Adolescent diet and incidence of proliferative benign breast disease //Cancer Epidemiology and Prevention Biomarkers. – 2003. – Т. 12. – №. 11. – С. 1159-1167.
Su X. et al. Intake of fiber and nuts during adolescence and incidence of proliferative benign breast disease //Cancer Causes & Control. – 2010. – Т. 21. – №. 7. – С. 1033-1046.
Jung M. M. et al. Lifetime physical activity and the incidence of proliferative benign breast disease //Cancer Causes & Control. – 2011. – Т. 22. – №. 9. – С. 1297.
Ader D. N. et al. Cyclical mastalgia: prevalence and associated health and behavioral factors //Journal of Psychosomatic Obstetrics & Gynecology. – 2001. – Т. 22. – №. 2. – С. 71-76.
Rohan T. E., Miller A. B. Hormone replacement therapy and risk of benign proliferative epithelial disorders of the breast //European journal of cancer prevention: the official journal of the European Cancer Prevention Organisation (ECP). – 1999. – Т. 8.
O’Connell P. et al. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci //JNCI: Journal of the National Cancer Institute. – 1998. – Т. 90. – №. 9. – С. 697-703.
Hoogerbrugge-van der Linden N. et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. – 2003.
Беспалов В. Г., Травина М. Л. Фиброзно-кистозная болезнь и риск рака молочной железы (обзор литературы) //Опухоли женской репродуктивной системы. – 2015. – №. 4.
Ghosh K., Vierkant R.A. et al. Association between mammographic breast density and histologic features of benign breast disease. Breast Cancer Res. 2017.
Brinton L.A. Vessey M.P., Flavel R., et al. Risk factors for benign breast disease. Am J Epidemiol 1981;113:203–14.
Прилепская В. Н., Швецова О. Б. Доброкачественные заболевания молочных желез: принципы терапии В помощь практическому врачу //Гинекология. – 2000. – Т. 2. – №. 6. – С. 201-204.
Радзинский В. Е. Молочные железы и гинекологические болезни. – 2010.
Silvera S. A. N., Rohan T. E. Benign proliferative epithelial disorders of the breast: a review of the epidemiologic evidence //Breast cancer research and treatment. – 2008. – Т. 110. – №. 3. – С. 397-409.
Dyrstad S. W. et al. Breast cancer risk associated with benign breast disease: systematic review and meta-analysis //Breast cancer research and treatment. – 2015. – Т. 149. – №. 3. – С. 569-575.
Onstad M., Stuckey A. Benign breast disorders //Obstetrics and Gynecology Clinics. – 2013. – Т. 40. – №. 3. – С. 459-473.
Mendell L., Rosenbloom M., Naimark A. Are breast patterns a risk index for breast cancer? A reappraisal //American Journal of Roentgenology. – 1977. – Т. 128. – №. 4. – С. 547-547.
Boyd N. F. et al. Bias and the association of mammographic parenchymal patterns with breast cancer //British journal of cancer. – 1982. – Т. 45. – №. 2. – С. 179.
Brisson J., Morrison A. S., Khalid N. Mammographic parenchymal features and breast cancer in the breast cancer detection demonstration project //JNCI: Journal of the National Cancer Institute. – 1988. – Т. 80. – №. 19. – С. 1534-1540.
Janzon L., Andersson I., Petersson H. Mammographic patterns as indicators of risk of breast cancer. A cross-sectional population study //Radiology. – 1982. – Т. 143. – №. 2. – С. 417-419.
Byrne C. et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status //JNCI: Journal of the National Cancer Institute. – 1995. – Т. 87. – №. 21. – С. 1622-1629.
Fitzgibbons P. L., Henson D. E., Hutter R. V. P. Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement //Archives of pathology & laboratory medicine. – 1998. – Т. 122. – №. 12. – С. 1053.
Smith R. L., Pruthi S., Fitzpatrick L. A. Evaluation and management of breast pain //Mayo Clinic Proceedings. – Elsevier, 2004. – Т. 79. – №. 3. – С. 353-372.
Noroozian M. et al. Long-term clinical outcomes in women with breast pain in the absence of additional clinical findings: mammography remains indicated //Breast cancer research and treatment. – 2015. – Т. 149. – №. 2. – С. 417-424.
Plu-Bureau G. et al. Cyclical mastalgia and breast cancer risk: results of a French cohort study //Cancer Epidemiology and Prevention Biomarkers. – 2006. – Т. 15. – №. 6. – С. 1229-1231.
Мастопатии / [Андреева Е. Н., Боженко В. К., Бурдина И. И. и др.] ; под редакцией А. Д. Каприна, Н. И. Рожковой. - Москва : ГЭОТАР-Медиа, 2019.
Савельева Г. М. и др. Национальное руководство //Акушерство–М.: Гэотар-Медиа. – 2015.
National Comprehensive Cancer Network. Breast Cancer Risk Reduction. Version 1.2024 – October 31, 2023.
Ngo C., Seror J., Chabbert-Buffet N. Breast pain: recommendations //Journal de gynecologie, obstetrique et biologie de la reproduction. – 2015. – Т. 44. – №. 10. – С. 938-946.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Breast Cancer Screening and Diagnosis Version 3.2023 — October 31, 2023.
C. Ngô, J. Seror, and N. Chabbert-Buffet, “Breast pain: Recommendations,” J. Gynecol. Obstet. Biol. Reprod. (Paris)., vol. 44, no. 10, pp. 938–946, Dec. 2015, doi: 10.1016/j.jgyn.2015.09.039.
G. Page, “NCCN Guidelines for Breast Cancer V . 1 . 2023 – Annual on 10 / 28 / 22,” pp. 21–23, 2023.
Gorins A., Cordray J. P. Hormonal profile of benign breast disease and premenstrual mastodynia //European journal of gynaecological oncology. – 1984. – Т. 5. – №. 1. – С. 1-10.
Mancini A. et al. Endocrine evaluation of patients with benign lumps of the breast //Cancer detection and prevention. – 1992. – Т. 16. – №. 1. – С. 27-30.
Lauby-Secretan B. et al. Breast-cancer screening—viewpoint of the IARC Working Group //New England journal of medicine. – 2015. – Т. 372. – №. 24. – С. 2353-2358.
Speroff L., Fritz M. A. (ed.). Clinical gynecologic endocrinology and infertility. – lippincott Williams & wilkins, 2011.
Сметник В. П., Тумилович Л. Г. Неоперативная гинекология. – Медицинское информационное агентство, 2006. .
Diagnosis and management of benign breast disorders. Clinical management guidelines for obstetrician-gynecologists., Obstetrics & Gynecology., no. 127(6), pp. 141–156, 2016.
Рожкова Н. И. Рентгенодиагностика заболеваний молочной железы. – 1993., Медицина. Москва.
Henderson T. O. et al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer //Annals of internal medicine. – 2010. – Т. 152. – №. 7. – С. 444-455.
Abdullah P, Alabousi M et al. Synthetic 2D Mammography Versus Standard 2D Digital Mammography: A Diagnostic Test Accuracy Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2021.
Alabousi M, Zha N et al. Digital breast tomosynthesis for breast cancer detection: a diagnostic test accuracy systematic review and meta-analysis. Eur Radiol. 2020.
Лабазанова П.Г., Буданова М.В. и др. Маммографическая плотность – маркер повышенного риска развития рака молочной железы. Медицинский алфавит. 2021.
Методические рекомендации по использованию системы BI-RADS при маммографическом обследовании / Методические рекомендации под редакцией д.м.н., профессора, член-корреспондента РАН, Заслуженного деятеля науки РФ, А. Ю. Васильева. — Москва. — 2017.
Buchberger W. et al. Incidental findings on sonography of the breast: clinical significance and diagnostic workup //AJR. American journal of roentgenology. – 1999. – Т. 173. – №. 4. – С. 921-927.
Якобс О. Э., Рожкова Н. И., Каприн А. Д. Возможности соноэластографии при дифференциальной диагностике заболеваний молочной железы, сопровождающихся скоплением микрокальцинатов //Акушерство и гинекология: Новости. Мнения. Обучения. – 2017. – №. 1 (15).
Якобс, О. Э. Оптимизация ранней диагностики непальпируемого рака молочной железы на основе интеграции цифровых радиологических технологий //Автореф..дисс., докт мед наук., 2019.
Catalano O. et al. Additional role of colour Doppler ultrasound imaging in intracystic breast tumours //La radiologia medica. – 2009. – Т. 114. – №. 2. – С. 253.
Itoh A. et al. Breast disease: clinical application of US elastography for diagnosis //Radiology. – 2006. – Т. 239. – №. 2. – С. 341-350.
Weismann C., Mayr C., Egger H., and Auer A. Breast Sonography - 2D, 3D, 4D Ultrasound or Elastography? Breast Care (Basel)., vol. 6, no. 2, pp. 98–103, 2011, doi: 10.1159/000327504.
Lehman C. D. et al. Diagnostic accuracy of digital screening mammography with and without computer-aided detection //JAMA internal medicine. – 2015. – Т. 175. – №. 11. – С. 1828-1837.
Серов В. Н. и др. Руководство по амбулаторно-поликлинической помощи в акушерстве и гинекологии //М.: ГЭОТАР-Медиа. – 2016., ГЭОТАР-Мед. Москва.
Серов В. Н., Сухих Г. Т. Клинические рекомендации. Акушерство и гинекология //М: ГЭОТАР-Медиа.-4-е изд.-2017. Москва: Проблемы репродукции.
Heywang-Köbrunner S. H. et al. Contrast-enhanced MRI of the breast: accuracy, value, controversies, solutions //European journal of radiology. – 1997. – Т. 24. – №. 2. – С. 94-108.
Kriege M. et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition //New England Journal of Medicine. – 2004. – Т. 351. – №. 5. – С. 427-437.
Корженкова Г. П. Диагностическое значение категорий BI-RADS в ведении пациенток с доброкачественной патологией молочных желез //Опухоли женской репродуктивной системы. – 2016. – №. 4.
Адамян Л.В., Родионов В.В., Шешко Е.Л., Долгушина Н.В. Доброкачественная дисплазия молочной железы с позиции BI-RADS: современный взгляд на проблему. Проблемы репродукции. 2023.
ACR Breast Imaging Reporting and Data System, Breast Imaging Atlas; BI-RADS. Reston, VA: American College of Radiology.// American College of Radiology (ACR). ACR-BI-RADS®--5th Edition., 2014.
Адамян Л.В., Котова Е.Г., Родионов В.В., Протасова А.Э., Шешко Е.Л. Роль врача-гинеколога в выявлении патологии молочной железы и сочетанных гиперпролиферативных заболеваний. Проблемы репродукции. 2023.
Harvey J. A. et al. Short-term follow-up of palpable breast lesions with benign imaging features: evaluation of 375 lesions in 320 women //American Journal of Roentgenology. – 2009. – Т. 193. – №. 6. – С. 1723-1730.
Patterson S. K. et al. Outcomes of solid palpable masses assessed as BI-RADS 3 or 4A: a retrospective review //Breast cancer research and treatment. – 2014. – Т. 147. – №. 2. – С. 311-316.
Graf O. et al. Follow-up of palpable circumscribed noncalcified solid breast masses at mammography and US: can biopsy be averted? //Radiology. – 2004. – Т. 233. – №. 3. – С. 850-856.
Shin J. H. et al. Probably benign breast masses diagnosed by sonography: is there a difference in the cancer rate according to palpability? //American journal of roentgenology. – 2009. – Т. 192. – №. 4. – С. W187-W191.
Huff J. G. The sonographic findings and differing clinical implications of simple, complicated, and complex breast cysts //Journal of the National Comprehensive Cancer Network. – 2009. – Т. 7. – №. 10. – С. 1101-1105.
Daly C. P. et al. Complicated breast cysts on sonography: is aspiration necessary to exclude malignancy? //Academic radiology. – 2008. – Т. 15. – №. 5. – С. 610-617.
Venta L. A. et al. Management of complex breast cysts //AJR. American journal of roentgenology. – 1999. – Т. 173. – №. 5. – С. 1331-1336.
Doshi D. J. et al. Complex cystic breast masses: diagnostic approach and imaging-pathologic correlation //Radiographics. – 2007. – Т. 27. – №. suppl_1. – С. S53-S64.
Guray M., Sahin A.A. Benign breast diseases: classification, diagnosis, and management. Oncologist. 2006 May;11(5):435-49.
Shetty M. K., Shah Y. P. Prospective evaluation of the value of negative sonographic and mammographic findings in patients with palpable abnormalities of the breast //Journal of ultrasound in medicine. – 2002. – Т. 21. – №. 11. – С. 1211-1220.
Moy L. et al. Specificity of mammography and US in the evaluation of a palpable abnormality: retrospective review //Radiology. – 2002. – Т. 225. – №. 1. – С. 176-181.
Leung S. E., Ben-Nachum I., Kornecki A. New Palpable Breast Lump With Recent Negative Mammogram: Is Repeat Mammography Necessary? //American Journal of Roentgenology. – 2016. – Т. 207. – №. 1. – С. 200-204.
Гарифуллова Ю. В. Лучевые методы диагностики доброкачественных заболеваний молочных желез //Практическая медицина. – 2017. – №. 7 (108).
Hussain A. N., Policarpio C., Vincent M. T. Evaluating nipple discharge //Obstetrical & gynecological survey. – 2006. – Т. 61. – №. 4. – С. 278-283.
Jain A. et al. Management of nipple discharge: technology chasing application //The breast journal. – 2010. – Т. 16. – №. 4. – С. 451-452.
Tokuda Y, Kuriyama K, Nakamoto A, Choi S, Yutani K, Kunitomi Y, Haneda T, Kawai M, Masuda N, Takeda M, Nakamura H. Evaluation of suspicious nipple discharge by magnetic resonance mammography based on breast imaging reporting and data system magnetic resonance imaging descriptors. J Comput Assist Tomogr. 2009 Jan-Feb;33(1):58-62. doi: 10.1097/RCT.0b013e3181671ad2. PMID: 19188786.
Ballesio L. et al. Role of breast magnetic resonance imaging (MRI) in patients with unilateral nipple discharge: preliminary study //La radiologia medica. – 2008. – Т. 113. – №. 2. – С. 249-264.
Ashfaq A. et al. Validation study of a modern treatment algorithm for nipple discharge //The American Journal of Surgery. – 2014. – Т. 208. – №. 2. – С. 222-227.
Abati A., Simsir A. Breast fine needle aspiration biopsy: prevailing recommendations and contemporary practices //Clinics in laboratory medicine. – 2005. – Т. 25. – №. 4. – С. 631-654.
P. Levine, A. Simsir, and J. Cangiarella, “Management Issues in Breast Lesions Diagnosed by Fine-Needle Aspiration and Percutaneous Core Breast Biopsy,” Pathol. Patterns Rev., vol. 125, no. suppl_1, pp. S124–S134, Jun. 2006, doi: 10.1309/ADTMEE684PN89DQG.
Rosolowich V. et al. Mastalgia //Journal of Obstetrics and Gynaecology Canada. – 2006. – Т. 28. – №. 1. – С. 49-57.
B. R. Mason, K.-A. Page, and K. Fallon, Mason B. R., Page K. A., Fallon K. An analysis of movement and discomfort of the female breast during exercise and the effects of breast support in three cases //Journal of Science and Medicine in Sport. – 1999. – Т. 2. – №. 2. – С. 134-144.
Yeow K. M. et al. Ultrasound-guided core needle biopsy as an initial diagnostic test for palpable breast masses //Journal of Vascular and Interventional Radiology. – 2001. – Т. 12. – №. 11. – С. 1313-1317.
Egyed Z. et al. Radial scar-significant diagnostic challenge //Pathology & Oncology Research. – 2008. – Т. 14. – №. 2. – С. 123.
Murshid K. R. A review of mastalgia in patients with fibrocystic breast changes and the non-surgical treatment options //Journal of Taibah University Medical Sciences. – 2011. – Т. 6. – №. 1. – С. 1-18.
Fox H. et al. Are patients with mastalgia anxious, and does relaxation therapy help? //The Breast. – 1997. – Т. 6. – №. 3. – С. 138-142.
Barros A. C. S. D. et al. Reassurance in the treatment of mastalgia //The breast journal. – 1999. – Т. 5. – №. 3. – С. 162-165.
Родионов В. В., Сметник А. А. Доброкачественные заболевания молочных желез //Акушерство и гинекология: Новости. Мнения. Обучения. – 2018. – №. 1 (19).
Faiz O., Fentiman I. S. Management of breast pain //International journal of clinical practice. – 2000. – Т. 54. – №. 4. – С. 228-232.
Goodwin P. J. et al. Elevated high-density lipoprotein cholesterol and dietary fat intake in women with cyclic mastopathy //American journal of obstetrics and gynecology. – 1998. – Т. 179. – №. 2. – С. 430-437.
Boyd N. F. et al. Effects at two years of a low-fat, high-carbohydrate diet on radiologic features of the breast: results from a randomized trial //Journal of the National Cancer Institute. – 1997. – Т. 89. – №. 7. – С. 488-496.
Winkler U. H. et al. Cyclic progestin therapy for the management of mastopathy and mastodynia //Gynecological Endocrinology. – 2001. – Т. 15. – №. sup6. – С. 37-43.
Меских Е. В., Рожкова Н. И. Применение прожестожеля при диффузных формах мастопатии //Опухоли женской репродуктивной системы. – 2012. – №. 1.
КОГАН И. Ю., Мусина Е. В. Местное применение микронизированного прогестерона у больных репродуктивного возраста с мастопатией //Акушерство и гинекология. – 2012. – №. 2. – С. 102-106.
Протасова А.Э., Андреева Е.Н. и др. Динамика клинических симптомов фиброзно–кистозной мастопатии на фоне трансдермального геля микронизированного прогестерона: результаты российского многоцентрового наблюдательного исследования БРЕСТ. Акушерство и гинекол.
Андреева Е.Н., Рожкова Н.И. Эффективность трансдермального геля, содержащего микронизированный прогестерон, в лечении фиброзно-кистозной мастопатии (ФКМ). Результаты российского исследования. Акушерство и гинекология. 2016.
Протасова А.Э. Динамика клинических симптомов фибрознокистозной мастопатии на фоне монотерапии препаратом трансдермального микронизированного прогестерона: результаты многоцентрового когортного исследования БРЕСТ-2. Акушерство и гинекология. 2020.
M. Brkic et al., “The Influence of Progesterone Gel Therapy in the Treatment of Fibrocystic Breast Disease,” Open J. Obstet. Gynecol., vol. 06, no. 05, pp. 334–341, 2016, doi: 10.4236/ojog.2016.65042.
Высоцкая И.В., Летягин В.П., Лактионов К.П. Диагностика и лечение доброкачественных заболеваний молочных желез (клинические рекомендации Российского общества онкомаммологов). Опухоли женской репродуктивной системы. 2014:19-32.
J. S. Kaiser, M. A. Helvie, R. L. Blacklaw, and M. A. Roubidoux, “Palpable breast thickening: role of mammography and US in cancer detection.,” Radiology, vol. 223, no. 3, pp. 839–844, Jun. 2002, doi: 10.1148/radiol.2233011166.
O. J. Kjartansdottir, L. G. Sigurdardottir, E. J. Olafsdottir, J. G. Jonasson, G. Ursin, and L. Tryggvadottir, “Estrogen-progestin use and breast cancer characteristics in lean and overweight postmenopausal women.,” Breast Cancer Res. Treat., vol. 163, no. 2, pp. 363–373, Jun. 2017, doi: 10.1007/s10549-017-4171-2.
Fentiman I.S., “The pathophysiology and therapy of benign breast disease,” Reprod. Med. Mol. Cell. Genet. Fundam., vol. 97, pp. 487–494, 2003.
Рожкова Н. И., Меских Е. В. Применение Мастодинона при различных формах мастопатии //Опухоли женской репродуктивной системы. 2010;3:27–34.
Mirzaee F, Fakari FR, Babakhanian M, Roozbeh N, Ghazanfarpour M. The Effectiveness of Herbal Medicines on Cyclic Mastalgia: A Systematic Review on Meta-analysis. Rev Bras Ginecol Obstet. 2022 Oct;44(10):972-985. doi: 10.1055/s-0042-1755456. Epub 2022 Nov 29. PMID: 36446563; PMCID: PMC9708400.
Киселёв В. И. Сметник А. А., Сметник В. П., и др. Опыт применения индол-3-карбинола в лечении заболеваний молочной железы и профилактике рака молочной железы // Акушерство и гинекология №. 2. – С. 106-112., 2017.
Halaska M. et al. Treatment of cyclical mastalgia with a solution containing a Vitex agnus castus extract: results of a placebo-controlled double-blind study //The Breast. – 1999. – Т. 8. – №. 4. – С. 175-181.
Ooi S.L., Watts S., McClean R., Pak S.C. Vitex Agnus-Castus for the Treatment of Cyclic Mastalgia: A Systematic Review and Meta-Analysis. J. Womens Health. 2020; 29(2): 262-78.
Муйжнек Е. Л. и др. Фибросклероз и склерозирующий аденоз с микрокальцинатами в молочной железе. Молекулярный патогенез, своевременная диагностика и лечение //Research’n Practical Medicine Journal. – 2019. – Т. 6. – №. 2.
Киселев В.И., Сметник В.П., Сутурина Л.В., Селиванов С.П., Рудакова Е.Б., Рахматуллина И.Р. и др. Инолкарбинол – метод мультитаргетной терапии при циклической мастодинии. Акушерство и гинекология. 2013;7:56-62.
Сметник А. А., Сметник В. П., Киселев В. И. Опыт применения индол-3-карбинола в лечении заболеваний молочной железы и профилактике рака молочной железы //Акушерство и гинекология. – 2017. – №. 2. – С. 106-112.
Ашрафян Л.А., Рожкова Н.И., Прокопенко С.П., Меских Е.В., Артымук Н.В., Белоцерковцева Л.Д., Долгушина В.Ф., Коротких Н.В., Кузнецова Л.В., Кукарская И.И., Кононенко Т.С., Марочко Т.Ю., Соколов К.А., Вербицкая Ю.С. Влияние препарата индолкарбинола на течение циклической масталгии на фоне доброкачественной дисплазии молочной железы в условиях рутинной клинической практики (исследование «АФРОДИТА»). Акушерство и гинекология. 2024; 2: 134-142.
Гусейнов А.З., Гусейнов Т.А., Федорищев В.И. Эффективность индинола форто в консервативной терапии кистозной и смешанной форм фиброзно-кистозной мастопатии // Вестник новых медицинских технологий. Электронное издание. 2023.
Синицын В. А., Руднева Т. В. Лечение больных с фиброзно-кистозной мастопатией, сопровождающейся болевым синдромом //Рос вестн акуш гинекол. – 2006. – Т. 2. – С. 1-2.
Srivastava A., Mansel R. E. , Arvind N., Prasad K., Dhar A., and Chabra A. Evidence-based management of Mastalgia: a meta-analysis of randomised trials. Breast, vol. 16, no. 5, pp. 503–512, Oct. 2007, doi: 10.1016/j.breast.2007.03.003.
Sinha M. K., Barman A., Sahu S., Jha A. K., and Asharaf A. A. Tamoxifen in Mastalgia: A Meta-Analysis. J. Obstet. Gynaecol. Canada JOGC = J. d’obstetrique Gynecol. du Canada JOGC, vol. 44, no. 10, pp. 1084–1094, Oct. 2022, doi: 10.1016/j.jogc.2022.06.006.
Santen R. J., Mansel R. Benign breast disorders //New England Journal of Medicine. – 2005. – Т. 353. – №. 3. – С. 275-285.
Colak T., Ipek T., Kanik A., Ogetman Z., Aydin S. Efficacy of topical nonsteroidal antiinflammatory drugs in mastalgia treatment. J.Am.Coll.Surg. 2003.
Высоцкая И. В., Летягин В. П. Атипичные гиперплазии молочной железы //Опухоли женской репродуктивной системы. – 2015. – №. 4.
Coutant C. et al. Benign proliferative breast disease with and without atypia //Journal de gynecologie, obstetrique et biologie de la reproduction. – 2015. – Т. 44. – №. 10. – С. 980-995.
Foulkes R.E., Heard G., Boyce T., Skyrme R., Holland P.A., and Gateley C.A. Duct Excision is Still Necessary to Rule out Breast Cancer in Patients Presenting with Spontaneous Bloodstained Nipple Discharge. Int. J. Breast Cancer, vol. 2011, p. 495315, 2011, doi: 10.4061/2011/495315.
Высоцкая И. В. и др. Клинические рекомендации Российского общества онкомаммологов по профилактике рака молочной железы, дифференциальной диагностике, лечению предопухолевых и доброкачественных заболеваний молочных желез //Опухоли женской репродуктивной системы.
Li X. et al. A retrospective observational study of intraductal breast papilloma and its coexisting lesions: A real‐world experience //Cancer Medicine. – 2020.
Wu D, Shi AP, Song AL, Fan ZM. Clinical practice guidelines for intraductal papilloma: Chinese Society of breast surgery (CSBrS) practice guidelines 2021.
Kjartansdottir O. J. et al. Estrogen–progestin use and breast cancer characteristics in lean and overweight postmenopausal women //Breast cancer research and treatment. – 2017. – Т. 163. – №. 2. – С. 363-373.
Kaiser J. S. et al. Palpable breast thickening: role of mammography and US in cancer detection //Radiology. – 2002. – Т. 223. – №. 3. – С. 839-844.
А. Е. Н. Сухих Г. Т., Сметник В.П., “Менопаузальная гормонотерапия и сохранение здоровья женщин зрелого возраста. Клинические рекомендации: протоколы //,” Клинические рекомендации (протокол лечения), p. 30, 2015.
White A. J. et al. Lifetime alcohol intake, binge drinking behaviors, and breast cancer risk //American journal of epidemiology. – 2017. – Т. 186. – №. 5. – С. 541-549.
Dixon-Suen S.C., Lewis S.J., Martin R.M. on behalf of the Breast Cancer Association Consortium, et al. Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation studyBritish Journal of Sports Medicine 2022.
Yenen M.C. et al. Hormone replacement therapy in postmenopausal women with benign fibrocystic mastopathy // Climacteric. – 2003. – №6(2). – С. 146-150.
Lubin F. et al. Nutritional factors associated with benign breast disease etiology: a case-control study //The American journal of clinical nutrition. – 1989. – Т. 50. – №. 3. – С. 551-556.
Collaborative Group on Hormonal Factors in Breast Cancer et al. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet. 1997; 350: 1047-1059.
Matteo Lazzeroni et all. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study. DOI: 10.1200/JCO.22.02900 Journal of Clinical Oncology 41, no. 17 (June 10, 2023.
Sessa C., Balmaña J., Bober S.L., Cardoso M.J., Colombo N., et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Annals of Oncology. 2023; 34(1): 33-47.
De Felice F. et al. Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis //Annals of surgical oncology. – 2015. – Т. 22. – №. 9. – С. 2876-2880.
Loving V. A. et al. Targeted ultrasound in women younger than 30 years with focal breast signs or symptoms: outcomes analyses and management implications //American Journal of Roentgenology. – 2010. – Т. 195. – №. 6. – С. 1472-1477.
Д. Н. В. Сухих Г.Т., Прилепская В.Н., Аганезова Н.В., Андреева Е.Н., Баранов И.И., “Национальные критерии приемлемости контрацепции,” Адаптированный документ «Медицинские критерии приемлемости использования методов контрацепции ВОЗ, 5 издание, 2015», 2023.
R. T. Burkman, “Oral contraceptives: current status.,” Clin. Obstet. Gynecol., vol. 44, no. 1, pp. 62–72, Mar. 2001, doi: 10.1097/00003081-200103000-00010.
A. E. Schindler, “Non-contraceptive benefits of oral hormonal contraceptives.,” Int. J. Endocrinol. Metab., vol. 11, no. 1, pp. 41–47, 2013, doi: 10.5812/ijem.4158.
H. Zhu, X. Lei, J. Feng, and Y. Wang, “Oral contraceptive use and risk of breast cancer: a meta-analysis of prospective cohort studies.,” Eur. J. Contracept. Reprod. Heal. care Off. J. Eur. Soc. Contracept., vol. 17, no. 6, pp. 402–414, Dec. 2012, doi: 10.3109/13625187.2012.715357.
P. G. Moorman et al., “Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.,” J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., vol. 31, no. 33, pp. 4188–4198, Nov. 2013, doi: 10.1200/JCO.2013.48.9021.
D. Fitzpatrick, K. Pirie, G. Reeves, J. Green, and V. Beral, “Combined and progestagen-only hormonal contraceptives and breast cancer risk: A UK nested case-control study and meta-analysis.,” PLoS Med., vol. 20, no. 3, p. e1004188, Mar. 2023, doi: 10.1371/journal.pmed.1004188.
2015. WHO, “Medical eligibility criteria for contraceptive use.”
Curtis K. M. et al. US medical eligibility criteria for contraceptive use, 2016. – 2016.
K. Wang, F. Li, L. Chen, Y.-M. Lai, X. Zhang, and H.-Y. Li, “Change in risk of breast cancer after receiving hormone replacement therapy by considering effect-modifiers: a systematic review and dose-response meta-analysis of prospective studies.,” Oncotarget, vol. 8, no. 46, pp. 81109–81124, Oct. 2017, doi: 10.18632/oncotarget.20154.
Román M. et al. Postmenopausal hormone therapy and breast cancer prognostic characteristics: a linkage between nationwide registries //Cancer Epidemiology and Prevention Biomarkers. – 2016. – Т. 25. – №. 11. – С. 1464-1473.
Сухих Г. Т. и др. Менопаузальная гормонотерапия и сохранение здоровья женщин зрелого возраста. Клинические рекомендации: протоколы //Клинические рекомендации (протокол лечения)./ГТ Сухих, ВП Сметник, ЕН Андреева− М. – 2015. – С. 30.
“The 2022 hormone therapy position statement of The North American Menopause Society.,” Menopause, vol. 29, no. 7, pp. 767–794, Jul. 2022, doi: 10.1097/GME.0000000000002028.
J.-S. Yuk, “Relationship between menopausal hormone therapy and breast cancer: A nationwide population-based cohort study.,” Int. J. Gynaecol. Obstet. Off. organ Int. Fed. Gynaecol. Obstet., Mar. 2024, doi: 10.1002/ijgo.15461.
A. Fournier, F. Berrino, and F. Clavel-Chapelon, “Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study.,” Breast Cancer Res. Treat., vol. 107, no. 1, pp. 103–111, Jan. 2008, doi: 10.1007/s10549-007-9523-x.
R. L. Prentice et al., “Estrogen plus progestin therapy and breast cancer in recently postmenopausal women.,” Am. J. Epidemiol., vol. 167, no. 10, pp. 1207–1216, May 2008, doi: 10.1093/aje/kwn044.
Y. Vinogradova, C. Coupland, and J. Hippisley-Cox, “Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases.,” BMJ, vol. 371, p. m3873, Oct. 2020, doi: 10.1136/bmj.m3873.
N. Colacurci, D. Mele, P. De Franciscis, V. Costa, N. Fortunato, and L. De Seta, “Effects of tibolone on the breast.,” Eur. J. Obstet. Gynecol. Reprod. Biol., vol. 80, no. 2, pp. 235–238, Oct. 1998, doi: 10.1016/s0301-2115(98)00129-8.
Liu Y. et al. Intakes of alcohol and folate during adolescence and risk of proliferative benign breast disease //Pediatrics. – 2012. – Т. 129. – №. 5. – С. e1192-e1198.
Frazier A. L., Rosenberg S. M. Preadolescent and adolescent risk factors for benign breast disease //Journal of Adolescent Health. – 2013. – Т. 52. – №. 5. – С. S36-S40.
Cui Y. et al. Menstrual and reproductive history, postmenopausal hormone use, and risk of benign proliferative epithelial disorders of the breast: a cohort study //Breast cancer research and treatment. – 2009. – Т. 114. – №. 1. – С. 113-120.
Lauby-Secretan B. et al. Body fatness and cancer—viewpoint of the IARC Working Group //New England Journal of Medicine. – 2016. – Т. 375. – №. 8. – С. 794-798.
Heinemann K. et al. Benign gynecological tumors: estimated incidence: results of the German Cohort Study on Women’s Health //European Journal of Obstetrics & Gynecology and Reproductive Biology. – 2003. – Т. 107. – №. 1. – С. 78-80.
R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer Statistics, 2017.,” CA. Cancer J. Clin., vol. 67, no. 1, pp. 7–30, Jan. 2017, doi: 10.3322/caac.21387.
Ritte R. et al. Height, age at menarche and risk of hormone receptor‐positive and‐negative breast cancer: A cohort study //International journal of cancer. – 2013. – Т. 132. – №. 11. – С. 2619-2629.
Eliassen A. H. et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women //Journal of the National Cancer Institute. – 2006. – Т. 98. – №. 19. – С. 1406-1415. .
Kerlikowske K. et al. Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk //Journal of the National Cancer Institute. – 2007. – Т. 99. – №. 5. – С. 386-395.
Qu X. et al. Bone mineral density and risk of breast cancer in postmenopausal women //Breast cancer research and treatment. – 2013. – Т. 138. – №. 1. – С. 261-271.
Kaaks R. et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC) //Journal of the National Cancer Institute. – 2005. – Т. 97. – №. 10. – С. 755-765.
Hormones T. E. et al. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies //The lancet oncology. – 2010. – Т. 11. – №. 6. – С. 530-542.
Gunter M. J. et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women //Journal of the National Cancer Institute. – 2009. – Т. 101. – №. 1. – С. 48-60.
Nichols H. B. et al. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006 //Journal of Clinical Oncology. – 2011. – Т. 29. – №. 12. – С. 1564.
Kuchenbaecker K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers //Jama. – 2017. – Т. 317. – №. 23. – С. 2402-2416.
Gram I. T. et al. Smoking and risk of breast cancer in a racially/ethnically diverse population of mainly women who do not drink alcohol: the MEC Study //American journal of epidemiology. – 2015. – Т. 182. – №. 11. – С. 917-925.
Fachi M.M., de Deus Bueno L., de Oliveira D.C., da Silva L.L., Bonetti A.F. Efficacy and safety in the treatment of hyperprolactinemia: A systematic review and network meta-analysis. J Clin Pharm Ther. 2021 Dec;46(6):1549-1556. doi: 10.1111/jcpt.13460. Epub 2021 Jun 16. PMID: 34137053.
Baer H.J., Schnitt S.J., Connolly J.L., Byrne C., Willett W.C., Rosner B., et al. Early life factors and incidence of proliferative benign breast disease. Cancer Epidemiol Biomarkers Prev. 2005; 14(12):2889–2897.
Berkey C.S., Willet W.C., Frazier A.L. Prospective study of adolescent alcohol consumption and risk of benign breast disease in young women. Pediatrics. 2010;125(5):1081-1087.
Liu Y., Tamimi R.M., Berkey C.S., Willet W.C. et al. Intakes of alcohol and folate during adolescence and risk of proliferative benign breast disease. Pediatrics. 2012;129(5):1192-1198.
Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study J. Natl. Cancer Inst. 2005;97(22):1652-1662.
Vogel V.G., Costantino J.P., Wickerham D.L., et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer Cancer Prev. Res. (Phila). 2010;3(6):696-706.
Goss P.E., Ingle J.N., Ales-Martinez J.E. et al. Exemestane for breast cancer prevention in postmenopausal women J. Natl. Cancer Inst. 2011;364:2381-2391.
Ашрафян Л.А., Рожкова Н.И., Прокопенко С.П. и др. Влияние препарата индолкарбинола на течение циклической масталгии на фоне доброкачественной дисплазии молочной железы в условиях рутинной клинической практики (исследование «АФРОДИТА») Акушерство и гинекология. 2024; 2: 134-142 https://dx.doi.org/10.18565/aig.2024.35
Rand T. et al. MRI of microadenomas in patients with hyperprolactinaemia //Neuroradiology. – 1996. – Т. 38. – С. 744-746.
Gao Y, Saksena MA, Brachtel EF, terMeulen DC, Rafferty EA. How to approach breast lesions in children and adolescents. Eur J Radiol. 2015 Jul;84(7):1350-64.
Lee EJ, Chang YW, Oh JH, Hwang J, Hong SS, Kim HJ. Breast Lesions in Children and Adolescents: Diagnosis and Management. Korean J Radiol. 2018 Sep-Oct;19(5):978-991. doi: 10.3348/kjr.2018.19.5.978. Epub 2018 Aug 6.
Cozzi A, Di Leo G, Houssami N, Gilbert FJ, Helbich TH, Álvarez Benito M, Balleyguier C et. al. Preoperative breast MRI positively impacts surgical outcomes of needle biopsy-diagnosed pure DCIS: a patient-matched analysis from the MIPA study. Eur Radiol. 2024 Jun;34(6):3970-3980.
Istomin A, Masarwah A, Pitkänen M, Joukainen S, Sutela A, Vanninen R, Sudah M. Galactography is not an obsolete investigation in the evaluation of pathological nipple discharge. PLoS One. 2018 Oct 8;13(10):e0204326.
Hubbard TJ, Sharma A, Ferguson DJ. Breast pain: assessment, management, and referral criteria. Br J Gen Pract. 2020 Jul 30;70(697):419-420.
Höller M, Steindl H, Abramov-Sommariva D, Kleemann J, Loleit A, Abels C, Stute P. Use of Vitex agnus-castus in patients with menstrual cycle disorders: a single-center retrospective longitudinal cohort study. Arch Gynecol Obstet. 2024 May;309(5):2089-2098. Epub 2024 Feb 23.
Mareti E, Vatopoulou A, Spyropoulou GA, Papanastasiou A, Pratilas GC, Liberis A, Hatzipantelis E, Dinas K. Breast Disorders in Adolescence: A Review of the Literature. Breast Care (Basel). 2021 Apr;16(2):149-155.
Chowdhury R, Sinha B, Sankar MJ, Taneja S, Bhandari N, Rollins N, Bahl R, Martines J. Breastfeeding and maternal health outcomes: a systematic review and meta-analysis. Acta Paediatr. 2015 Dec;104(467):96-113.